



INTEGRATED ENDOCRINE SYSTEM


Hormone Actions

G-protein	Receptor and ligand	Second messenger
G _q -alpha subunit	“Hav1 M and M-GOT”	↑ IP3 ↑ DAG
G _s -alpha subunit	FSH, LH, ACTH, TSH, CRH, hCG, ADH-V ₂ , MSH, PTH, Calcitonin, H2, Glucagon, GHRH All B receptors	↑ cAMP
G _i -alpha subunit	MAD 2	↓ cAMP
Receptor Guanyl cyclase	BAN	↑ cGMP




Glutamate	Ligand-gated ion channels: NMDA, AMPA
GABA	Ligand-gated: GABA A, GABA C (B-GPCR)
Acetylcholine	Nicotinic → Ligand-gated
Norepinephrine, 5HT, Dopamine, Ach-M	GPCR (<i>except 5HT3 which is ligand-gated</i>)





STEROIDS PREP TV

Intranuclear:
 Cytoplasmic:



INSULIN PIPE


PIGGLET

Diabetes mellitus - Diagnosis


HbA1c	FBS	RBS	OGTT-75g

Stages of Type 1 DM
Stage 1: Auto-Ab
Stage 2: Auto-Ab + Dysglycemia
Stage 3: Auto-Ab + Dysglycemia + Symptoms


	Type 1 DM Adult onset: LADA Antibodies:	Type 2 DM	MODY AD MC type: Gene:
Age of onset			
Habitus			
Insulin levels			
B cell mass			
OHG			



Insulin



Increase Insulin Secretion	Decrease Insulin Secretion
Increased blood glucose/ FFA / AA	Decreased blood glucose / fasting
Gastrointestinal hormones (gastrin, cholecystinin, secretin, GIP)	Somatostatin
Glucagon, growth hormone, cortisol	Leptin
β -Adrenergic stimulation	α -Adrenergic activity
Insulin resistance (obesity)	





Preproinsulin (RER)
 Proinsulin (stored in secretory granules)
 Insulin (51aa) and C-peptide
 Biphasic release:

Metabolic syndrome: NCEP-ATP III

- Central obesity:**
 >102 cm (India-90cm) in men
 >88 cm (India-80cm) in women
- Elevated triglycerides:** >150 mg/dL
- HDL**
 < 40 mg/dL in men
 < 50 mg/dL in women.
- Blood pressure:** >130/85 mm Hg
- Fasting glucose:** >100 mg/dL

DM




Affreza: Inhalational –Postprandial
Good glycemic control can reduce:
Mortality:
MC microvascular complication:
MC type:



- Drugs causing DM:**
- Steroids
 - Thiazide
 - Niacin
 - Phenytoin
 - PI
 - Clozapine
 - B Agonists
 - IFN alpha

DKA-HHS

ISPAD guidelines for DKA






- Add IV potassium if serum K ≤ 5.2 mEq/L
- Hold insulin for serum K < 3.3 mEq/L
- Hco3 if pH < 6.9

	DKA	HHS
Glucose		
ABG		
Ketones		
Demographic		
Pathophysiology		
Mortality		


Agent	Mechanism of action	Side effects
Sulfonylureas Chlorpropamide, Glipizide, Glyburide Meglitinides Repaglinide, Nateglinide	Increases insulin secretion by inhibiting B-cell K ⁺ ATP channels	Hypoglycemia , Weight gain Safe in renal failure (Max-Glipizide/ Glicazide) Chlorpropamide:
Biguanides Metformin	Stimulates AMP kinase, decreasing insulin resistance	Lactic acidosis, Weight loss, Vit B12 deficiency, Diarrhea Max reduction in HbA1c
Thiazolidinediones Pioglitazone, Rosiglitazone	Activates transcription regulator PPAR- γ , decreasing insulin resistance	Weight gain, Heart failure, Hepatotoxic, Fractures, CME Risk of bladder cancer - MI-
GLP-1 agonists Exenatide, Liraglutide, Tirazepatide-SC Semaglutide-Oral / SC DPP4 inhibitors : ORAL Sitagliptin, Saxagliptin, Linagliptin	Increases glucose-dependent insulin secretion, decreases glucagon secretion, delays gastric emptying Useful in CV risk mortality GLP-2 agonist: GLP-1 + GLP-2 agonist:	Increase satiety, Weight loss Pancreatitis, MTC – Nasopharyngitis- GLP1- safe in renal failure except: DPP4 - CI in renal failure except: Monitor LFT: Vidagliptin CYP metabolized:
Amylin Analogue Pramlintide	Decreases glucagon secretion, delays gastric emptying	Increase satiety
α-glucoside inhibitors Acarbose , Miglitol, Voglibose	Reduces intestinal disaccharide absorption	Diarrhea, Flatulence CI in IBD
SGLT2 Inhibitors Canagliflozin, Dapagliflozin Sotagliflozin:	Increases renal glucose excretion Useful in CV risk mortality Only if eGFR >20	Urinary tract infections, Fournier gangrene, Polyuria Weight loss, Fractures Euglycemic ketoacidosis
Bromocriptine, bile acid sequesterant (colesevalam, ranolazine)		

Hormone-Graphs



Autocrine
Paracrine
Endocrine

Pituitary hormones



GnRH agonists-Goserelin, Nafarelin, Leuprolide

Continuous :


Pulsatile:

GnRH antagonists-Ganirelix, Cetrorelix

GHRH analog- Tesamorelin

Mecasermin:

Hypopituitarism + Hyperprolactinemia + Central Diabetes Insipidus
Triphasic response:







Anterior Pituitary

Amenorrhea, infertility,
galactorrhea

PRL:
RULE OUT:
TSH
RFT
UPT
Drugs

Post-partum Failure to
lactate, Amenorrhea,
Fatigue,
Hypoglycemia
PRL / GH/ TSH

Sudden headache,
visual deficit
Pre-existing adenoma





Insulin tolerance test

Initial:
Confirmatory:
Management:
Unresectable:

CUSHING SYNDROME

“A BIG FIB”



CUSHING SYNDROME:
MCC:
IOC to confirm-

ACTH

Low

High

High dose DMS:

Supress

Not supressed


Neutrophil:
Eosinphil:
Lymphocytes:

Nelson syndrome: Hyperpigmentation + Headache/visual symptoms
H/o B/L adrenalectomy for Cushing syndrome

Posterior Pituitary

Polydipsia-Polyuria

	SIADH	Central DI	Nephrogenic DI	Primary polydipsia
Urine Osm				
Plasma Osm				
Serum Na				
Uric acid				
Diagnosis	Water loading test: ADH high	Water deprivation test: Osm low	Water deprivation test: Osm low	Water deprivation test: Osm >600 mosm/kg
Management				



D/D:
 Hypovolemic HypoNa + SAH
 High BNP → Natriuresis →
 Increased Urinary Na⁺


Barter-Schwartz Criteria for SIADH:

- Clinically Euvolemic
- Low Serum Osmolality <275
- Urine Osmolality >100 or Urine Na⁺ > 40meq/L
- Absence of Any Renal, Thyroid disease, diuretic use
- Correction with fluid restriction

ADH: V1-
 V2
 V3-

SIADH causes: Chlorpropamide, Oxcarbamazepine, Cyclophosphamide, Vincristine, SSRI, Small cell ca lung, Pneumonia, Encephalitis

ADRENAL INSUFFICIENCY



IOC:
COSYNTROPIN TEST

HIGH
CORTISOL

LOW
CORTISOL
<20ug/dl

ACTH

LOW

HIGH

Primary versus central adrenal insufficiency

	Primary	Secondary
Most common cause	Autoimmune/ Granulomatous	Chronic glucocorticoid therapy
Cortisol		
ACTH		
Aldosterone		
Clinical features	<ul style="list-style-type: none"> Severe symptoms Hyperpigmentation Hyperkalemia 	<ul style="list-style-type: none"> Less severe No hyperpigmentation No hyperkalemia

HYPERALDOSTERONISM

CAUSES

- Bilateral nodular hyperplasia
- Hyperfunctioning adrenal adenoma

↑ Aldosterone

EFFECTS ON ELECTROLYTES

- ↑ K⁺ excretion → Hypokalemia
- ↑ H⁺ excretion → Metabolic alkalosis
- ↑ Na⁺ reabsorption → Hypertension + Blood volume

RAAS EFFECT


- ↓ Renin
- ↓ Angiotensin II

ALDOSTERONE ESCAPE

- Limits edema
- Limits hypernatremia

↑ Na⁺ excretion

Hypertension + hypokalemia



Pheochromocytoma

Headache / Sweating / Palpitation

Initial Ix-

Confirm Ix-

Best to localize-

Biopsy/ FNAC-

Best for mets-

Best for extraadrenal pheo-

MC site for extraadrenal pheo-

Rule of 10 :


-Extradrenal/ No hypertension/ Children

-B/L But 50% in

-Malignant But 40% in

-Familial

Treatment:



Carcinoid tumor

Origin:

MC site:

Urinary:

Skin flushing

Heart valve disease

Intestinal diarrhea

Vasospasm



Asthma

Rx:

Telotristat-



Rule of 1/3: Mets, 2nd malignancy, multiple

Thyroid hormone










- **Brain maturation**
- **Bone O'clast +**
- $\uparrow \beta_1$ receptors in heart
- **Basal metabolic rate \uparrow** (via $\uparrow Na^+/K^+-ATPase$)
- **Blood sugar \uparrow** (\uparrow glycogenolysis, gluconeogenesis)
- **Break down lipids \uparrow** (\uparrow lipolysis)
- **Babies: stimulates surfactant synthesis**

Graves Disease



- 1-Only signs
- 2-Soft tissue involvement
- 3: Proptosis
- 4: Extraocular muscle involvement
- 5: Corneal involvement
- 6: Sight loss (optic nerve involvement)



Staring look	
Absent creases in the forehead on superior gaze	
Hyperpigmentation of the superior eye folds	
Loss of the lateral third of eyebrows	
Retraction of upper eye lid	
Lid lag of the upper eyelid on downward gaze	
Inability to converge	

Treatment

Management of Graves

RADIO-IODINE
ABLATION

DRUGS

SURGERY


Thyroid storm

- Beta blockers
- PTU
- Glucocorticoids
- Sodium iodide
- If asthma + A-fib:


Myxedema coma

IV T3 and/or L-thyroxine (T4)
IV Hydrocortisone
0.9% NaCl if $\text{Na}^+ < 120 \text{ mEq/L}$
Treat hypothermia (temperature $< 35 \text{ }^\circ\text{C}$)

Parathyroid and calcium




↑ Serum Ca^{2+} → stimulation of parafollicular (C) cells of the thyroid → ↑ calcitonin
Inhibits osteoclastic bone resorption



Intermittent/ 1-34 aa chain PTH:

Hypercalcemia



- Primary (or tertiary) hyperparathyroidism
- Familial hypocalciuric hypercalcemia
- Lithium

- Malignancy
- Vitamin D toxicity
- Granulomatous diseases
- Thiazides
- Milk-alkali syndrome
- Thyrotoxicosis
- Vitamin A toxicity
- Immobilization

Management:

- Severe (Calcium > 14 mg/dL) or Symptomatic
- Normal saline hydration plus calcitonin
 - Avoid loop diuretics unless volume overload (heart failure) exists

Long-term treatment: Bisphosphonate